Major remarks: 1. The authors identify all low-dose aspirin users in two time periods and divide them in patients who were prescribed aspirin in < 20% of the days compared to patients who got aspirin prescribed in > 80% of the days for a period of 60-days. In my opinion, this selection contains two major problems. The first problem is bias by indication. Both groups were not randomly selected, there is a reason why some patients got aspirin frequently prescribed, and some patients occasionally. Controlling for characteristics measured, like comorbidity, age, etc, might nog be sufficient to adjust for all existing (and not measured) difference between both groups. Therefore, the current conclusion is, in my opinion, not supported by the presented results and thus too firm. I think that the conclusion should maximally contain the word that it is suggested that occasionally, in the short term, might be less harmful. This requires adjusting the title as well. The second major problem I see with the selection is the very short time-frame. Low-dose aspirin is given to prevent vascular diseases from the start of prescription onwards into the long run. It seems unlikely that the physician wants to prevent just for 60 days (or 180 days) vascular diseases. So, the authors just studied whether there is a risk difference in the start-up phase of low-dose aspirin, and not whether there is an overall (lifetime) harmful effect. This should be made much more prominent, as the current manuscript might suggest something else.
2. The number of performed statistical analyses is very large, therefore the authors should adjust for multiple testing, 3. The absolute numbers of events is rather low, both for haemorrhage as for ischemia, given tha large cohort of over 63,000 patients. This suggests also some prudence in the conclusion.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Question 1: This is an interesting and important paper which contributes to the debate over the risk and benefit of aspirin in primary prevention. Overall the study is well conducted and written. Answer 1: Thanks! Question 2: The title should contain information on the study design. Answer 2: We have added information about the study design in the research title. Thanks! Question 3: The Abstract methods are difficult to follow. It is not clear that occasional and regular users are compared in both studies. Answer 3: We have revised the Abstract (Please see p. 3).
Question 4: There is insufficient information in the introduction on the recommendations or prescribing patterns for aspirin in primary prevention in Taiwan. Is it recommended for particular high risk population groups, certain age groups etc? Answer 4: Thanks! We have added additional information in Introduction section (Please see the 2nd paragraph of p. 6).
Question 5: Was interaction between variables considered in the analysis? -specifically between comorbidities and type of aspirin use?
Answer 5: Please see the following table in RED and the 2nd paragraphs of p. 15 and p. 18 in the main text. We did not see the significant interaction between comorbidities and type of aspirin use. Table. Rate differences and net clinical risk for major event by the interaction of comorbidities and type of low-dose aspirin use in a 60-day follow-up period of NHI 2000.1 Characteristic Hemorrhage (n = 94) Ischemia (n = 624) Adjusted net clinical risk3,4 (95% CI) Use of low-dose aspirin Rate difference2 Use of low-dose aspirin Rate difference2 < 20%  80% Crude Adjusted4 < 20%  80% Crude Adjusted4 n (%) n (%) Hypertension No 7 (0.09) 35 (0.32) 0.23% 0.28%** 10 (0.12) 281 (2.54) -2.42% -2.28%*** 2.56%*** (2.22%, 2.909%) Yes 4 (0.10) 48 (0.32) 0.22% 0.27%*** 15 (0.38) 318 (2.11) -1.73% -1.65%*** 1.91%*** (1.56%, 2.26%) Adjusted Difference (Yes vs. No) 0.072% (-0.25%, 0.39%) 0.36% (-0.27%, 0.99%) -0.28% (-1.00%, 0.423%) Diabetes No 6 (0.06) 53 (0.28) 0.22% 0.24%*** 22 (0.21) 449 (2.37) -2.16% -2.06%*** 2.30%*** (2.04%, 2.57%) Yes 5 (0.30) 30 (0.42) 0.12% 0.27% 3 (0.18) 150 (2.10) -1.92% -1.89%*** 2.15%*** (1.64%, 2.67%) Adjusted Difference (Yes vs. No) 0. 029% (-0.02%, 0.80%) 0.17% (-0.50%, 0.85%) 0.12% (-0.73%, 0.97%) Peptic ulcer No 10 (0.10) 70 (0.31) 0.21% 0.23%*** 20 (0.19) 539 (2.37) -2.18% -2.10%*** 2.32%*** (2.08%, 2.57%) Yes 1 (0.06) 13 (0.39) 0.33% 0.53%* 5 (0.31) 60 (1.81) -1.50% -1.37%*** 1.90%*** (11.9%, 2.61%) Adjusted Difference (Yes vs. No) 0.078% (-0.83%, 0.99%) 0.47% (-0.46%, 1.40%) -0.39% (-1.71%, 0.92%) Charlson index score < 3 8 (0.07) 64 (0.30) 0.23% 0.25%*** 22 (0.21) 496 (2.30) -2.09% -2.03%*** 2.28%*** (2.04%, 2.53%)  3 3(0.23) 19 (0.42) 0.19% 0.29% 3 (0.23) 103 (2.29) -2.06% -1.91%*** 2.20%*** (1.50%, 2.91%) Adjusted Difference (Yes vs. No) 0.012% (-0.66%, 0.68%) -0.038% (-1.29%, 0.53%) 0.04% (-0.76%,1.53%) Abbreviation: CI = Confidence interval; IHD = Ischemic heart disease; NHI = National Health Insurance; NSAID = Nosteroidal anti-inflammatory agents; PPI = Proton pump inhibitors. 1Major event includes hemorrhage (gastrointestinal hemorrhage or hemorrhagic stroke) or ischemia (ischemic stroke or acute myocardial infarction). 2Difference in rate of hemorrhage was calculated as (hemorrhage rateuse of low-dose aspirin ≥ 80%) -(hemorrhage rate use of low-dose aspirin < 20%); Difference in rate of ischemia was calculated as (ischemia rateuse of low-dose aspirin < 20%) -(ischemia rate use of low-dose aspirin ≥ 80%). 3Net clinical risk = [(hemorrhage rateuse of low-dose aspirin ≥ 80%) -(hemorrhage rate use of lowdose aspirin < 20%)] -[(ischemia rateuse of low-dose aspirin < 20%) -(ischemia rate use of low-dose aspirin ≥ 80%)]. 4Adjusting all variables listed in Table 1 . For subgroup analyses, all variables, except the variable was classified, listed in Table 1 was adjusted. Bootstrapping analysis was conducted with 1,000-time replications to compute differences of predicted adjusted rates and bootstrap standard errors. * indicates p < 0.05; ** indicates p < 0.01; *** indicates p < 0.001. Question 6: The conclusions in the abstract and Discussion need to be more clearly stated. The authors are not recommending occasional use but rather that aspirin not be used in primary prevention of vascular disease based on both the effectiveness in preventing ischemia and the risk of hemorrhage. Answer 6: We have revised them (Please see p. 4 and the 2nd paragraph of p. 25).
Question 7: The last sentence is unclear. I presume the authors mean: "This study's findings suggest caution against prescribing low-dose aspirin regularly to health patients..." Answer 7: Thanks! We have revised it (Please see the 2nd paragraph of p. 25).
Reviewer 2
Question 1: This is an interesting topic and the authors used a large database to study their question, Major remarks: The authors identify all low-dose aspirin users in two time periods and divide them in patients who were prescribed aspirin in < 20% of the days compared to patients who got aspirin prescribed in > 80% of the days for a period of 60-days. In my opinion, this selection contains two major problems. The first problem is bias by indication. Both groups were not randomly selected, there is a reason why some patients got aspirin frequently prescribed, and some patients occasionally. Controlling for characteristics measured, like co-morbidity, age, etc, might not be sufficient to adjust for all existing (and not measured) difference between both groups. Therefore, the current conclusion is, in my opinion, not supported by the presented results and thus too firm. I think that the conclusion should maximally contain the word that it is suggested that occasionally, in the short term, might be less harmful. This requires adjusting the title as well. Answer 1: To minimize the bias by indication in this study, we used several strategies: 1) we excluded patients not prescribed any aspirin during the prospective follow-up period from 1 January 2000 to 31 December 2009 (Please see the 2nd paragraph of p. 10); and 2) to control for all known potential confounders. Because this is an observational study, the unmeasured confounding factors are always the issue. We have added this limitation in the Discussion section (Please see the 1st paragraph of p. 25). We have revised our conclusions in the Abstract and Discussion sections and the research title as suggested by the reviewer (Please see p. 4 and the 2nd paragraph of p. 25). Thanks! Question 2: The second major problem I see with the selection is the very short time-frame. Low-dose aspirin is given to prevent vascular diseases from the start of prescription onwards into the long run. It seems unlikely that the physician wants to prevent just for 60 days (or 180 days) vascular diseases. So, the authors just studied whether there is a risk difference in the start-up phase of low-dose aspirin, and not whether there is an overall (lifetime) harmful effect. This should be made much more prominent, as the current manuscript might suggest something else. Answer 2: Thanks for the suggestions. We have added this limitation in the Discussion section and added one more sentence in the conclusion that "the future study should examine the long-term riskbenefit effect of low-dose aspirin in the primary prevention" (Please see p. 25).
Question 3: The number of performed statistical analyses is very large, therefore the authors should adjust for multiple testing, Answer 3: In the section of Introduction, we calculated the short-term risk-benefit effect of occasional and regular use of low-dose aspirin (≤ 100 mg per day) as a means of primary prevention in the general population of Taiwan (Please see the 2nd paragraph of p. 6). Because the analysis of the short-term risk-benefit of low-dose aspirin is our primary purpose in this study and the purpose of other analyses is to confirm our primary findings, the multiple testing for causing type-I error is unlikely in this study. Thanks! Question 4: The absolute numbers of events is rather low, both for haemorrhage as for ischemia, given the large cohort of over 63,000 patients. This suggests also some prudence in the conclusion. Answer 4: Thanks for the suggestion! We have made the conclusion more conservative (Please see the 2nd paragraph of p. 25).
VERSION 2 -REVIEW

REVIEWER
Mark Harris UNSW Australia REVIEW RETURNED 08-Nov-2014
GENERAL COMMENTS
The authors have responded to the issues raised in my previous review.
There are still two minor problems. 1. In the abstract conclusion and the Discussion the authors should more clearly state that this study suggests that Aspirin should not be be used in primary prevention. 2. The First sentence of the Discussion is not correctly expressed: "the risk of a shorttime regular use (almost daily use) of lowdose aspirin canceled out its possible contribution to preventing major vascular diseases, compared to those occasional users." Apart from the grammar, it should be stating that the risks outweighed the benefits" There are still a number of grammatical errors throughout the paper that need to be corrected. It may need to professionally edited.
REVIEWER
Joke Korevaar NIVEL Netherlands Institute for Health services Research
The Netherlands REVIEW RETURNED 26-Nov-2014
GENERAL COMMENTS
The authors addressed some of the major remarks, but I have still some major concerns.
The very short time-frame is still a concern. I still miss in de conclusion the remark that they studied the start-up phase of lowdose aspirin, and that the observed results could be different in the long run. There is some attention for this point in the conclusion of the discussion, although limited. There is no attention for this point in the final words of the abstract.
